M&A / Deals Merck’s deal for Terns sparks debate over a possible biotech bidding war BioPharma DiveSome investors and analysts believe the pharma s $6.7 billion offer is justified given Terns recent stock run.M&A / DealsRead full story pharminent March 26, 2026 (Last updated: March 27, 2026) BioPharma Dive Some investors and analysts believe the pharma s $6.7 billion offer is justified given Terns recent stock run. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA clears Denali drug in ‘clear step’ for rare disease biotechsNext: The Rare Journey Needs a Special Pharmacy Partner Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
